Xhale Assurance announced today the appointment of John Moscarillo as VP of Commercial Operations.
Mr. Moscarillo joins Xhale Assurance™ with outstanding credentials and a proven track record in sales, management, channel partnerships and corporate alliances. Mr. Moscarillo brings with him 17 years of valuable industry experience and has earned numerous awards and recognition in a variety of sales, sales training and sales management positions. His first duties will be in the sales and marketing of the Assurance® Alar/Nasal SpO2 Sensor which offers faster reflection of oxygen saturation changes and a dependable signal that is less prone to drop out.
Mr. Moscarillo initially joined Xhale in December 2013 as the National Business Development Manager of Xhale SMART. In November 2014, Mr. Moscarillo was promoted to Vice President of Commercial Operations for Xhale Assurance™ with responsibility for Sales, Business Development and Operations in both national and international markets.
Previously, while serving in progressive sales roles with Medtronic, Inc. and Phyiso Control, Inc., Mr. Moscarillo developed clinical experience in the hospital and pre-hospital markets with an emphasis on Cardiology, ICU, and Emergency Departments. Prior to that, Mr. Moscarillo spent five years in the pharmaceutical sales industry.
Mr. Moscarillo received a Bachelor of Arts degree from Longwood University.
Xhale, Inc. is a medical technology company developing and commercializing patient-centric monitoring solutions for the healthcare industry. Xhale is focused on developing two broad technology platforms. Through its Xhale Smart, Inc. subsidiary, Xhale is developing a medication adherence monitoring technology – the SMART® Adherence System – designed to verify, monitor, report, and improve adherence to medication regimens in clinical trials. The SMART® Adherence System is the only technology designed to offer definitive and noninvasive monitoring of medication adherence in near real-time, utilizing exhaled breath to confirm that medication has been taken as directed. Through its Xhale Assurance, Inc. subsidiary, Xhale is developing a patient monitoring technology, the Assurance® platform, designed to improve and expand the use of conventional pulse oximetry used in hospitals and other clinical settings to monitor critical patient parameters, as well as to increase the number of parameters which can be measured. Xhale’s first product based on this technology, the Assurance® Alar One-Sense™ pulse oximetry sensor, received marketing clearance in the United States. The Assurance® Alar One-Sense™ pulse oximetry sensor is a disposable sensor placed on a patient’s nasal ala which transmits heart rate and blood oxygenation information to an oximetry monitor.
Xhale, Inc. was founded in 2005 on technology licensed from the University of Florida.
For more information, please visit www.xhale.com or contact the company at email@example.com.